公开(公告)号：WO2022234853A1

公开(公告)日：2022-11-10

申请号：PCT/JP2022/019544

申请日：2022-05-06

Applicant: 中外製薬株式会社

Inventor： 河田　発夫 ,  鷹野　宏治 ,  小竹　智也 ,  陰　未来 ,  橋本　哲 ,  田宮　実 ,  若宮　佑真 ,  林　竜児 ,  森田　雄也

IPC: A61P43/00 ,  C07K5/083 ,  C07K7/54 ,  A61K38/06 ,  A61K38/12

Abstract: KRASを選択的に阻害する環状化合物、およびオリゴペプチド化合物を見出した。また、環状化合物の製造に有用なオリゴペプチド化合物および非天然アミノ酸を見出した。さらには、環状化合物およびオリゴペプチド化合物がKRASに特異的なアミノ酸残基と相互作用することを見出した。

公开(公告)号：WO2022234852A1

公开(公告)日：2022-11-10

申请号：PCT/JP2022/019542

申请日：2022-05-06

Applicant: 中外製薬株式会社

Inventor： 棚田　幹將 ,  鷹野　宏治 ,  松尾　篤 ,  田宮　実 ,  千代田　彩 ,  伊藤　俊也 ,  飯田　健夫 ,  太田　淳

IPC: A61K38/12 ,  A61P7/00 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  C07K1/02 ,  C07K1/04 ,  C07K1/06 ,  C07K7/06 ,  C07K7/64

Abstract: Rasと相互作用する環状ペプチド化合物、および該環状ペプチド化合物もしくはその塩またはそれらの溶媒和物を含む、医薬組成物を見出した。

公开(公告)号：WO2022222986A1

公开(公告)日：2022-10-27

申请号：PCT/CN2022/088117

申请日：2022-04-21

Applicant: MICROBIO (SHANGHAI) CO., LTD.

Inventor： CHANG, Yi-Chung ,  CHEN, Hui-Yu ,  YANG, Chi-Fan ,  CHEN, Huai-Yi

IPC: C07K7/64 ,  A61K47/64 ,  A61K38/12

Abstract: A conjugate comprising a cyclic peptide scaffold and one or more N-acetylgalactosamine (GalNAc) moieties. The conjugate may further carry a diagnostic or therapeutic agent for use in delivering the agent to liver cells. In some embodiments, the cyclic peptide may have 4-10 amino acid residues. The GalNAc moieties can be covalently bound to the cyclic peptide scaffold via a first linker and the agent can be covalently bound to the cyclic peptide scaffold via a second linker.

公开(公告)号：WO2022212513A1

公开(公告)日：2022-10-06

申请号：PCT/US2022/022559

申请日：2022-03-30

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA

Inventor： EVSEENKO, Denis ,  SHKHYAN, Ruzanna

IPC: A61K38/08 ,  A61P29/00 ,  A61K38/04 ,  A61K38/12 ,  A61P19/02 ,  A61K38/00

Abstract: The disclosure provides compounds and method useful for modulating gp130 biological activity. The disclosure also provides methods and compositions for treating disease and disorders associated with gp130 activity, particularly those associated with inflammation. The disclosure provides an isolated peptide comprising, consisting essentially of or consisting of 4-50 amino acids and containing the sequence QQ(PY)F, wherein the peptide interacts with c-SRC.

公开(公告)号：WO2022207580A2

公开(公告)日：2022-10-06

申请号：PCT/EP2022/058180

申请日：2022-03-28

Applicant: TRX BIOSCIENCES LIMITED

Inventor： GOODING, Daniel ,  BREW, John ,  BANNISTER, Robin M.

IPC: A61K9/00 ,  A61K9/107 ,  A61K31/05 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/44 ,  A61K31/4453 ,  A61K31/502 ,  A61K31/5377 ,  A61K31/553 ,  A61K31/58 ,  A61K31/7135 ,  A61K38/12 ,  A61K47/14 ,  A61K47/12 ,  A61K47/28 ,  A61K31/4418 ,  A61K31/496 ,  A61K9/0053 ,  A61K9/0095

Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C14-24 fatty acids, one or more free C14-24 fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.

公开(公告)号：WO2022198264A1

公开(公告)日：2022-09-29

申请号：PCT/AU2022/050249

申请日：2022-03-18

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： SHEPHERD, Robert ,  WEBSTER, Nina

IPC: A61K31/28 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/505 ,  A61K31/506 ,  A61K31/513 ,  A61K38/12

Abstract: A pharmaceutical composition comprising at least one endothelin A receptor inhibitor or a pharmaceutically acceptable salt thereof and at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2022193902A1

公开(公告)日：2022-09-22

申请号：PCT/CN2022/076774

申请日：2022-02-18

Applicant: 亚飞上海生物医药科技有限公司

Inventor： 魏巍 ,  刘辰 ,  陈斌 ,  刘源 ,  白远超

IPC: A61K38/12 ,  C40B50/06 ,  C40B70/00

Abstract: 一种环状化合物库及其构建方法，利用固相载体、含光可裂解基团的分子、连接分子、合成砌块、两端的关环A端分子和关环B端分子反应合成，利用光照下分解的方法脱去固相载体，利用关环A端分子A和关环B端分子B的氨基酸残基结构在环合酶作用下进行完成关环。所述方法，关环条件温和，普适性更强，扩充了编码化合物库的化学反应类型和化合物库多样性空间。

公开(公告)号：WO2022186782A1

公开(公告)日：2022-09-09

申请号：PCT/SG2022/050117

申请日：2022-03-07

Applicant: NANYANG TECHNOLOGICAL UNIVERSITY

Inventor： LIU, Chuan Fa ,  XIA, Yiyin ,  TAM, James P.

IPC: C12P21/04 ,  C07K7/64 ,  C07K14/00 ,  A61K38/12 ,  A61K38/16

Abstract: The present invention relates to methods that employ enzymes having Asn-specific cyclase activity as a means for generating cyclic (poly)peptides from (poly)peptides that comprise a ligation motif comprising a Nγ-hydroxy-L-asparagine or Nγ-amino-L-asparagine residue. Further encompassed are the resulting cyclic (poly)peptides and the corresponding uses.

公开(公告)号：WO2022178379A1

公开(公告)日：2022-08-25

申请号：PCT/US2022/017211

申请日：2022-02-22

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： PEI, Dehua ,  BUYANOVA, Marina

IPC: C07K7/64 ,  A61K38/12 ,  A61K38/05

Abstract: Provided herein are novel cyclic cell penetrating peptides comprising at least two arginines and at least three hydrophobic amino acids. The disclosure also provides methods of using the cyclic cell penetrating peptides to transport cargo into cells and to treat diseases.

公开(公告)号：WO2022108883A1

公开(公告)日：2022-05-27

申请号：PCT/US2021/059416

申请日：2021-11-15

Applicant: HOFSETH BIOCARE ASA ,  FRAMROZE, Bomi

Inventor： CURRIE, Crawford Linden Alexander

IPC: A01N37/18 ,  A61K38/12 ,  C07K1/14

Abstract: Provided herein are methods for treating certain inflammatory and/or respiratory conditions, disorders and diseases in humans using compositions comprising lipopeptides, including microcolins. The compositions are orally administered. The humans suitable for such treatments include those largely resistant to medical and surgical interventions, such as steroid treatments. The compositions described herein have also been found to reduce eosinophil effector function.